Modality
ASO
MOA
JAK1/2i
Target
USP1
Pathway
Cell Cycle
MM
Development Pipeline
Preclinical
Jan 2021
→ Nov 2026
PreclinicalCurrent
NCT07476311
285 pts·MM
2021-07→2025-10·Active
NCT06164062
2,258 pts·MM
2021-01→2026-11·Not yet recruiting
2,543 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-146mo agoInterim· MM
2026-11-288mo awayInterim· MM
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2025-10-14 · 6mo ago
MM
Interim
2026-11-28 · 8mo away
MM
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07476311 | Preclinical | MM | Active | 285 | EDSS |
| NCT06164062 | Preclinical | MM | Not yet recr... | 2258 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Talazumab | Zealand Pharma | Phase 1/2 | WEE1 | |
| CGO-9628 | CG Oncology | Phase 2/3 | AuroraA | |
| Peminaritide | iTeos | NDA/BLA | CD20 |